fda approves nasal spray antidepressant Spravato gupta pkg newday vpx_00014920.jpg
PHOTO: Janssen Pharmaceuticals
fda approves nasal spray antidepressant Spravato gupta pkg newday vpx_00014920.jpg
Now playing
02:08
FDA approves ketamine-like nasal spray for depression
Saudi Crown Prince Mohammed bin Salman attends a conference in the Saudi capital Riyadh on October 2018.
PHOTO: FAYEZ NURELDINE/AFP/Getty Images
Saudi Crown Prince Mohammed bin Salman attends a conference in the Saudi capital Riyadh on October 2018.
Now playing
02:10
US intel report: Saudi Crown Prince responsible for approving Khashoggi operation
PHOTO: CNN
Now playing
09:36
I lost everything: Texas mom's devastating story from winter storm
The Pentagon, the headquarters of the US Department of Defense, located in Arlington County, across the Potomac River from Washington, DC is seen from the air January 24, 2017.  / AFP PHOTO / Daniel SLIM        (Photo credit should read DANIEL SLIM/AFP via Getty Images)
PHOTO: Daniel Slim/Getty Images
The Pentagon, the headquarters of the US Department of Defense, located in Arlington County, across the Potomac River from Washington, DC is seen from the air January 24, 2017. / AFP PHOTO / Daniel SLIM (Photo credit should read DANIEL SLIM/AFP via Getty Images)
Now playing
05:24
US carries out airstrikes on Iran-backed militia groups
A woman walks past mailboxes  seen outside of a US Post Office in Washington, DC on August 17, 2020. - The United States Postal Service is popularly known for delivering mail despite snow, rain or heat, but it faces a new foe in President Donald Trump. Ahead of the November 3 elections in which millions of voters are expected to cast ballots by mail due to the coronavirus, Trump has leveled an unprecedented attack at the USPS, opposing efforts to give the cash-strapped agency more money as part of a big new virus-related stimulus package, even as changes there have caused delays in mail delivery. (Photo by MANDEL NGAN / AFP) (Photo by MANDEL NGAN/AFP via Getty Images)
PHOTO: Mandel Ngan/AFP/Getty Images
A woman walks past mailboxes seen outside of a US Post Office in Washington, DC on August 17, 2020. - The United States Postal Service is popularly known for delivering mail despite snow, rain or heat, but it faces a new foe in President Donald Trump. Ahead of the November 3 elections in which millions of voters are expected to cast ballots by mail due to the coronavirus, Trump has leveled an unprecedented attack at the USPS, opposing efforts to give the cash-strapped agency more money as part of a big new virus-related stimulus package, even as changes there have caused delays in mail delivery. (Photo by MANDEL NGAN / AFP) (Photo by MANDEL NGAN/AFP via Getty Images)
Now playing
02:49
Biden announces 3 nominees to USPS board
PHOTO: CNN
Now playing
02:00
Weekend hindered by rain in the East and snow in the Northwest
The exterior of the U.S. Capitol building is seen at sunrise on February 8, 2021 in Washington, DC. The Senate is scheduled to begin the second impeachment trial of former U.S. President Donald J. Trump on February 9.
PHOTO: Sarah Silbiger/Getty Images
The exterior of the U.S. Capitol building is seen at sunrise on February 8, 2021 in Washington, DC. The Senate is scheduled to begin the second impeachment trial of former U.S. President Donald J. Trump on February 9.
Now playing
01:57
Senate parliamentarian rules against minimum wage increase in relief bill
Now playing
03:56
Marjorie Taylor Greene's challenger explains decision to run
Everyone wears masks and desks are spaced at the high school, where full in-person teaching has been offered since the school year began.
PHOTO: CNN
Everyone wears masks and desks are spaced at the high school, where full in-person teaching has been offered since the school year began.
Now playing
03:20
Ohio school is staying open with these safety measures
PHOTO: CNN
Now playing
03:44
Acting US Capitol Police chief explains 'operational challenges' from January 6 riot
Rep. Marie Newman (D-IL) speaks with CNN
PHOTO: CNN
Rep. Marie Newman (D-IL) speaks with CNN's Alisyn Camerota.
Now playing
07:17
Lawmaker reacts to Rep. Taylor Greene's tweet on her transgender daughter
An activist wears a "Fight For $15" T-shirt during a news conference prior to a vote on the Raise the Wage Act July 18, 2019 at the U.S. Capitol in Washington, DC. The legislation would raise the federal minimum wage from $7.25 to $15 by 2025.  (Photo by Alex Wong/Getty Images)
PHOTO: Alex Wong/Getty Images
An activist wears a "Fight For $15" T-shirt during a news conference prior to a vote on the Raise the Wage Act July 18, 2019 at the U.S. Capitol in Washington, DC. The legislation would raise the federal minimum wage from $7.25 to $15 by 2025. (Photo by Alex Wong/Getty Images)
Now playing
02:59
How to make sense of the minimum wage debate
AURORA, CO - DECEMBER 15: (EDITORIAL USE ONLY) Rocky Mountain Regional VA Medical Center investigational pharmacy technician Sara Berech prepares a dose of the Johnson & Johnson COVID-19 vaccine for a clinical trial on December 15, 2020 in Aurora, Colorado. The Johnson & Johnson vaccine could be submitted for emergency use by late January and is the only vaccine among leading candidates given as a single dose. (Photo by Michael Ciaglo/Getty Images)
PHOTO: Michael Ciaglo/Getty Images
AURORA, CO - DECEMBER 15: (EDITORIAL USE ONLY) Rocky Mountain Regional VA Medical Center investigational pharmacy technician Sara Berech prepares a dose of the Johnson & Johnson COVID-19 vaccine for a clinical trial on December 15, 2020 in Aurora, Colorado. The Johnson & Johnson vaccine could be submitted for emergency use by late January and is the only vaccine among leading candidates given as a single dose. (Photo by Michael Ciaglo/Getty Images)
Now playing
02:46
FDA says Johnson & Johnson vaccine is safe and effective
AUGUSTA, GEORGIA - NOVEMBER 15: Tiger Woods of the United States looks on from the third tee during the final round of the Masters at Augusta National Golf Club on November 15, 2020 in Augusta, Georgia. (Photo by Patrick Smith/Getty Images)
PHOTO: Patrick Smith/Getty Images
AUGUSTA, GEORGIA - NOVEMBER 15: Tiger Woods of the United States looks on from the third tee during the final round of the Masters at Augusta National Golf Club on November 15, 2020 in Augusta, Georgia. (Photo by Patrick Smith/Getty Images)
Now playing
02:43
Tiger Woods' team gives an update on his condition
Connolly
PHOTO: CNN
Connolly
Now playing
03:51
'I will not be lectured' on bipartisanship: Lawmaker fires back at Jim Jordan
PHOTO: KCAL/KCBS
Now playing
01:37
Official details speaking with Woods in moments following accident
PHOTO: CNN
Now playing
04:15
Experts: Former CIA agent victim of microwave weapon in Moscow
(CNN) —  

The US Food and Drug Administration approved Janssen Pharmaceuticals Inc.’s esketamine on Tuesday for treatment-resistant depression; the drug is the chemical cousin of ketamine, the powerful anesthetic that has been used illegally as the club drug Special K.

It will be sold as Spravato. More specifically, it’s for patients who have tried at least two other medications without success, and it should be taken with an oral antidepressant.

“There has been a longstanding need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products at the FDA’s Center for Drug Evaluation and Research, said in a news release announcing the approval.

Spravato is a nasal spray administered by an approved health care provider in a doctor’s office or a medical clinic. It may also be self-administered but only under the supervision of a care provider and cannot be taken home.

“Because of [safety] concerns, the drug will only be available through a restricted distribution system and it must be administered in a certified medical office where the health care provider can monitor the patient,” Farchione said.

Depending on the severity of the patient’s depression, it is given either once a week or once every other week.

Esketamine is an  option for patients with treatment-resistant depression.
PHOTO: Courtesy Janssen Pharmaceuticals, Inc.
Esketamine is an option for patients with treatment-resistant depression.

The drug is rapidly acting, so it starts working faster than other antidepressants, according to Janssen. It works by restoring brain cells in patients with treatment-resistant depression.

Currently available treatments for major depression are ineffective in 30% to 40% of patients. According to the FDA, there is one other approved medication for treatment-resistant depression, Symbyax, which was approved in 2009.

Side effects of Spravato include dizziness, nausea, vertigo, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, decreased sensitivity, sedation and dissociation, a feeling of being temporarily “disconnected” from your body and your mind.

The drug label will contain a “boxed warning” to alert patients to the risk of “sedation, and difficulty with attention, judgment and thinking (dissociation), abuse and misuse, and suicidal thoughts and behaviors after administration of the drug,” the agency said in its announcement.

Because of these risks, patients must be monitored for at least two hours after being given the drug.

Get CNN Health's weekly newsletter

Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.

In clinical trials, six patients who were taking the drug died, three from suicide, but FDA background materials reviewed by the advisory committee that recommended approval last month said, “It is difficult to consider these deaths as drug-related.”

Because of the drug’s close relationship to ketamine, experts have raised concerns about its potential for misuse and abuse, but clinical trials found those risks to be unfounded.

Concerns have also been raised about a lack of long-term data on possible health effects, most notably cognitive ones.

The drug was designated as a breakthrough therapy in 2013, a status intended to “expedite the development and review of drugs for serious or life-threatening conditions,” the FDA said at the time.

Greg Panico, a spokesman for Janssen, a division of Johnson & Johnson, did not say when Spravato will be available. He wrote in an email, “We are working quickly to educate and certify treatment centers on the unique administration requirements of SPRAVATO™ to ensure patients can access this important medicine.”

As for the cost, it will be “generally comparable with other specialty mental health drugs,” Panico said: about $590 to $885 per treatment session, based on the dosage and not accounting for mandatory discounts or negotiated rebates.

CNN’s Michael Nedelman and Ben Tinker contributed to this report.